Does release of CGRP from mouse brainstem slices indicate central inhibitory effect of triptans and kynurenate?
As observed earlier for other drugs used in the treatment of migraine this indicates that the central terminals in the spinal trigeminal nucleus may be the main site of action. The preparation allows evaluating the trigeminal brainstem as a pharmacological site of action.
As we found two different profiles, our approach may contribute to the important question: what intervention works for whom?